Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

Finch Therapeutics bags $53m for microbiome therapies

In race to be first-to-market in C diff

- PMLiVE

MSD taps Austria’s Themis to bolster vaccine pipeline

First big pharma partner for measles virus vector platform

- PMLiVE

GSK preps filings for BCMA-targeting multiple myeloma drug

On course to file before end of year

- PMLiVE

Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate

Judgement arrives ahead of European approval

- PMLiVE

BeiGene gets speedy US review for lymphoma drug zanubrutinib

First US filing is major milestone for Chinese firm

- PMLiVE

NICE’s long-serving chief exec Sir Andrew Dillon to step down

Pharma leader praises "laser focus" on thorny access questions

- PMLiVE

Pfizer goes big on gene therapy with $500m facility spend

Continues to build on its growing gene therapy business

Empowered patients: shaking the foundations of healthcare

Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...

Blue Latitude Health

- PMLiVE

AZ’s Imfinzi combo bombs again in non-small cell lung cancer

Ends AZ’s main challenge to Keytruda for first-line use

AstraZeneca AZ

AstraZeneca buys FDA priority review voucher from Sobi

Picks up coveted voucher for $95m

- PMLiVE

NICE’s fast-track catapults Skyrizi into market

Watchdog also gives direction on comparing rival treatments

- PMLiVE

Roche’s Hemlibra scores broader NHS funding

Expands to around 2,000 patients in England

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links